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Endovascular interventions for TASC II D
femoropopliteal lesions
Donald T. Baril, MD, Rabih A. Chaer, MD, Robert Y. Rhee, MD, Michel S. Makaroun, MD, and
Luke K. Marone, MD, Pittsburgh, Penn
Background: Advances in endovascular techniques have provided new options in the treatment of complex infrainguinal
occlusive lesions. The purpose of this study was to evaluate outcomes of endovascular interventions on TransAtlantic
InterSociety (TASC) II D femoropopliteal occlusive disease.
Methods: All patients undergoing endovascular interventions for femoropopliteal occlusive disease between July 2004 and
July 2009 were reviewed. Patient demographics, pre- and postprocedure ankle-brachial indices (ABI) and anatomic
factors were analyzed. Outcomes evaluated included primary patency, assisted-patency, secondary patency, predictors of
restenosis, and wound healing.
Results: Five hundred eighty-five limbs were treated during the period reviewed. The study group included 79 TASC D
limbs in 74 patients (mean age 76.5  11.9 years, male sex: 53%). Fifty-six limbs (71%) underwent treatment for critical
limb ischemia, including 42 (53%) with tissue loss. Eleven patients (15%) had previous failed bypasses. Preoperative ABIs
were unobtainable for 23 patients, while the remaining 56 had a mean baseline ABI of 0.54  0.28. There was one
periprocedural mortality. Five patients (6.3%) had periprocedural complications. Mean increase in ABI postprocedure
was 0.49 0.35. Follow-up was available for 74 limbs at a mean of 10.7 months (range, 1-35). There were 18mortalities
(24.3%) during the follow-up period. No patient required a major amputation during this follow-up period. Twenty-one
limbs (26.6%) experienced restenosis and nine limbs (11.4%) experienced occlusion. Twenty-nine limbs underwent
reintervention during the follow-up time, including nine which underwent multiple reinterventions. Primary, assisted-
primary, and secondary patency rates at 12 and 24 months were 52.2%, 88.4%, 92.6% and 27.5%, 74.2%, and 88.9%,
respectively. Predictors of restenosis/occlusion included hypercholesterolemia, the presence of a popliteal artery stent,
and patients who were current or former smokers.
Conclusions: Endovascular interventions for TASC II D lesions can be safely performed with excellent hemodynamic
improvement and limb salvage rates. Restenosis is not uncommon in this population, which mandates strict follow-up.
Further follow-up is necessary to determine the long-term efficacy of these interventions. (J Vasc Surg 2010;51:1406-12.)The prevalence of peripheral arterial disease (PAD) is
nearly 30% for all Americans over the age of 70, resulting in
symptoms which may range from claudication to gan-
grene.1,2 Treatment of PAD traditionally consisted of con-
servative management for symptoms of claudication and
surgical management of patients with critical limb ischemia
(CLI). In recent years, the development of endovascular
techniques to treat PAD and their success has led to a more
aggressive posture in the treatment of PAD. Reported
initial technical success of greater than 90% and secondary
patency rates of greater than 80% at 2 years have been
published regarding the treatment of shorter-segment fem-
oropopliteal occlusive disease.3-6 Current TransAtlantic
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1406InterSociety Consensus Document on Management of Pe-
ripheral Arterial Disease (TASC) recommendations advo-
cate traditional surgical therapy for the treatment of more
complex TASC II D lesions.7 These lesions involve long
femoropopliteal segments, an independent predictor for
treatment failure, and anatomically challenged regions
(popliteal), which traditionally do not lend themselves to
stenting. Secondary to these concerns, interventional tech-
niques have not acquired significant support in the treat-
ment of these lesions. However, advances in endovascular
techniques including the utilization of the subintimal tech-
nique and advances in technology, specifically, the develop-
ment of re-entry devices and more flexible nitinol stents have
significantly contributed to overcoming these technical limi-
tations, making it possible to treat even the most complex
occlusive lesion with minimally invasive techniques.
Patients with more complex TASC D lesions often
present with CLI and suffer from significant comorbid
medical conditions placing them at high risk for traditional
open surgical bypass.8,9 Our group has previously reported
acceptable results in the interventional treatment of TASC
B and C lesions with a mean lesion length of 12 cm.6 To
date, no large series has been published that reports on the
results of endovascular intervention for TASC D lesions.
The objective of this report was to examine the outcomes of
endovascular therapy for the treatment of TASC D femo-
ropopliteal lesions.
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Patients. All patients undergoing endovascular inter-
ventions for femoropopliteal occlusive disease between July
2004 and July 2009 were retrospectively identified from a
prospectively maintained physician database. A total of 585
limbs underwent endovascular interventions. Out of this
cohort, 74 patients with 79 TASC D lesions were identi-
fied. These patients represent the basis of this report. Pa-
tients who underwent failed attempts at endovascular inter-
vention for a TASC D lesion were not included in the
outcomes analysis. Indications for intervention were either
lifestyle-limiting claudication (Rutherford 2/3) or limb
salvage (Rutherford 4/5). Therapy for the individual pa-
tient was dictated at the preference of the attending sur-
geon based on clinical presentation, noninvasive laboratory
findings, and findings at the time of angiography.
Patient data which were collected included: patient
demographics, comorbidities, pre- and postprocedure
ankle-brachial indices (ABI), duplex velocity data, and the
utilization of adjuvant medical therapy. Additionally, all
angiograms and corresponding angiographic reports were
retrospectively reviewed to determine TASC II classifica-
tion of the treated lesions and to determine the status of the
runoff vessels.
Procedures. Procedures were performed in either a
fixed-imaging hybrid operating room or in the interven-
tional angiography suite by vascular surgeons. All proce-
dures were performed with patients receiving local anesthe-
sia in addition to conscious sedation. Standard digital
subtraction techniques were employed to maximize image
quality while minimizing use of contrast agent. Patients
with preoperative renal insufficiency (baseline sCr  1.5
mg/dL) were routinely treated periprocedurally with oral
N-acytelcysteine and intravenous hydration. Arterial access
was performed via the common femoral artery through a
contralateral retrograde approach or an ipsilateral anter-
grade approach using 5F or 6F sheaths. A standard aorto-
gram and unilateral or bilateral runoff was performed uti-
lizing a power injector.
Interventions were performed following the adminis-
tration of systemic heparin (40-100 U/kg). Lesions were
crossed with an 0.035-inch wire. For complete occlusions,
a soft 0.035-inch glide wire (Terumo Medical Corp, Som-
erset, NJ) and a 4F or 5F glide catheter (Terumo Medical
Corp, Somerset, NJ) were utilized to cross in a subintimal
fashion. When necessary, a re-entry device, Outback LTD
(Cordis Endovascular, Warren, NJ) was employed to gain
access to the flow lumen. Re-entry was confirmed with
contrast injection prior to intervention. Balloon angio-
plasty was subsequently performed with a noncompliant
balloon (various manufacturers) for superficial femoral ar-
tery lesions or a semicompliant balloon (various manufac-
turers) for popliteal artery lesions to minimize dissection at
that anatomic location. Balloon diameter was selected
based on the angiographic measurements of the nondis-
eased artery proximal and distal to the lesion. Nominal
inflations were maintained for a minimum of 1 minute.Stents were implanted following balloon angioplasty for
the treatment of flow-limiting dissections or residual steno-
sis of 30% after angioplasty or at the discretion of the
operating surgeon. All stents utilized were nitinol self-
expanding stents (various manufacturers). Whenever mul-
tiple stents were utilized, a minimum overlap zone of 5 mm
was achieved. Access site closure was performed using
manual compression or with a closure device (various man-
ufacturers) following access site arteriography.
All patients were administered a 300-mg loading dose
of clopidogrel immediately following the procedure and
subsequently maintained on 75 mg daily for a minimum of
6 months. Patients who had previously been intolerant of
clopidogrel secondary to bleeding complications were ad-
ministered 325 mg of aspirin and maintained on 325
mg/d.
Follow-up. Patients were seen in follow-up initially at
1, 3, and 6months after their procedure. Patients were then
evaluated at 6-month intervals. Follow-up visits included
an office visit with a physician and noninvasive studies
including ankle-brachial indices, pulse volume recordings,
and complete arterial duplex ultrasound examinations of
the treated limb. Patients who developed recurrent symp-
toms, evidence of recurrent or novel stenoses on ultra-
sound, or significant ABI decreases (0.15) underwent
angiography. Follow-up data were gathered from hospital
visits and in-hospital imaging via our electronic medical
record system in addition to reports of patients’ clinic visits.
Additional mortality data were obtained from the Social
Security Death Index.
Definitions and classifications. Coronary artery dis-
ease was defined as a history of angina, myocardial infarc-
tion, or prior coronary artery revascularizations. Chronic
renal impairment was defined as a serum creatinine level of
1.5 mg/dL or greater or a patient on permanent dialysis.
Cerebrovascular disease included a history of stroke, tran-
sient ischemic attack, or previous carotid artery revascular-
ization. Hypertension was defined by medication require-
ment to maintain a systolic blood pressure less than 140
mm Hg. Hypercholesterolemia and diabetes were defined
based on patients who had elevated cholesterol levels (ei-
ther total or reduced HDL/LDL ratios) including those
who were on lipid-lowering agents and the use of insulin or
oral hypoglycemics, respectively.
TASC II D lesions were defined as chronic total occlu-
sions of the superficial femoral artery (SFA) 20 cm and
involving the popliteal artery or chronic total occlusions of the
popliteal artery and proximal trifurcation vessels7 (Fig 1).
Endovascular procedures were considered technically
successful when all lesions treated had a 20% residual
stenosis on completion angiography. Primary patency was
defined as the absence of restenosis or occlusion in the
treated arterial segment. Restenosis was defined as either a
return of patients’ symptoms in conjunction with noninva-
sive testing, which confirmed recurrent disease (ABI de-
crease 0.15, dampened pulse volume recordings, or evi-
dence of stenoses by duplex ultrasound peak systolic
velocity 300 cm/s or ratio 3.0) or based on duplex
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patients who had no clinical symptoms. Occlusion was
defined as a return of the patients’ symptoms in conjunc-
tion with absence of arterial flow on color duplex in the
treated vessel or, in asymptomatic patients, based on duplex
findings alone. Assisted-primary patency was achieved via
secondary endovascular interventions to treat restenoses
Fig 1. A, Preintervention angiogram demonstrating popliteal ar-
tery occlusion. B, Angiogram following successful popliteal artery
recanalization.involving the originally treated arterial segment. Additionalprocedures to treat lesions proximal or distal to the initially
treated segment were also considered secondary interven-
tions to achieve assisted-primary patency. Secondary pa-
tency was achieved utilizing additional endovascular proce-
dures,which involved recanalizingoccluded arterial segments.
Patients who underwent surgical bypass after occlusion of a
segment which had been treated using endovascular tech-
niques were not considered patent for this analysis.
Statistical analysis. An independent statistician per-
formed all advanced statistical analyses. Primary patency,
assisted-primary patency, and secondary patency rates were
calculated using survival curve analysis. Univariate regres-
sion analysis was used to determine possible preprocedural
and anatomic predictors of restenosis including comorbidi-
ties, indications for treatment, and anatomic factors. Vari-
ables with a P value .25 on univariate analysis were then
assessed in a multivariate regression analysis using Cox
proportional hazards modeling.
RESULTS
Patient population. During the time period re-
viewed, a total of 79 limbs in 74 patients were treated with
TASCD lesions. Twenty-three (29.1%) of these limbs were
Rutherford classification 2/3, while the remaining 56
(70.9%) were Rutherford classification 4/5. Of the 56
limbs that were treated for CLI 14 were for rest pain and 42
were for tissue loss. The mean age was 76.5 11.9 years. A
slight male predominance (53%) was noted, and the typical
comorbid features associated with PAD were identified
(Table I).
Mean preprocedural ABI was 0.54  0.28. Twenty-
three patients had unobtainable ABIs preoperatively sec-
ondary to inaudible Doppler signals at the ankle or due to
vessel incompressibility. When these patients were assigned
a preoperative ABI value of 0, the mean preprocedural ABI
was 0.38  0.40. Forty limbs (50.6%) had single-vessel
runoff, 27 (34.2%) had two-vessel runoff, and 12 limbs
(15.2%) had three-vessel runoff. Mean lesion length was
188.6  115.6 mm.
Immediate outcomes. Technical success was achieved
Table I. Patient and lesion characteristics
Characteristic %
Male sex 53%
Cerebrovascular disease 14%
Chronic renal insufficiency 18%
On hemodialysis 4%
Coronary artery disease 63%
Congestive heart failure 15%
Diabetes mellitus 38%
Hypercholesterolemia 65%
Hypertension 82%
Previous bypass 11%
Tobacco use
Active 19%
Prior 52%
2 infrapopliteal runoff vessels 51%in 89% of patients who underwent endovascular treatment
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at endovascular intervention for a TASC D lesion were not
included in the subsequent outcomes analysis. Four limbs
(5.1%) required an antegrade approach to facilitate success-
ful recanalization. An antegrade approach was selected
either after failure to advance a sheath over the iliac bifur-
cation or due to inability to push through a lesion following
successful sheath placement in the contralateral distal ex-
ternal iliac artery. Nine limbs (11.4%) necessitated the use
of a re-entry device. Popliteal artery stents (including all
levels) were placed in 38 limbs (48.1%). There was one
periprocedural death. This occurred in a 91-year-old female
patient with multiple comorbidities who presented with
advanced gangrenous changes in the involved limb. One
day following a successful endovascular intervention, the
next of kin decided to withdraw care and the patient
subsequently expired. Immediate complications occurred
following five interventions (6.3%). Three patients had
intraprocedural complications. This included distal embo-
lization in a patient who was successfully treated with
thrombolysis at the time of the procedure, a peroneal artery
perforation treated with coil embolization, and an extralu-
minal recanalization secondary to vessel rupture treated at a
second intervention with covered stents. Two patients had
postprocedural complications including a congestive heart
failure exacerbation necessitating a 1-day intensive care unit
stay and one patient who developed access site hemorrhage
requiring operative repair.
Follow-up. Mean follow-up length was 10.7 months
(range, 1-35months), excluding five patients whowere lost
to follow-up and the one patient who expired in the hospi-
tal. A total of 18 patients (24.3%) died during follow-up.
Mean immediate increase in ABI (measured within 1
month following intervention) was 0.49  0.35. This
included patients who preprocedure did not have an audi-
ble Doppler signal at the ankle and postprocedure had a
value which could then be obtained.
Thirty-seven patients whose initial indication for inter-
vention was tissue loss were followed. Thirty-three (89.2%)
of these patients demonstrated significant or complete
wound healing. Twelve patients (15.2%) did require minor
amputations either pre- or postprocedure, the majority (10
patients) of whom were able to heal their amputation sites
following their endovascular intervention. Included in this
cohort were five patients who underwent transmetatarsal
amputations and seven patients who underwent toe ampu-
tations. There were no major amputations during the
follow-up period, although three patients in the cohort did
require surgical revascularization for limb salvage. Of the
10 patients who could not be successfully revascularized
using endovascular techniques, six patients went on to
surgical bypass and four required a major amputation.
During the follow-up period, 30 limbs (38%) experi-
enced restenosis (21) or occlusions (9). By survival curve
analysis, primary patency was 52.2  7.5% at 12 months
and 27.5 9.4% at 24 months (Fig 2). Twenty-nine limbs
(36.7%) underwent reintervention during the follow-up
time. All patients had duplex findings consistent with reste-nosis or occlusion prior to reintervention. The one excep-
tion to this was a patient who inadvertently underwent
extraluminal recanalization and was treated with covered
stents. The mean time to reintervention was 7.5 months.
Nine limbs (11.4%) required multiple reinterventions in-
cluding 5 limbs which underwent 2 reinterventions, 3 limbs
which underwent 3 reinterventions, and 1 limbs which
underwent 4 reinterventions. Assisted-primary patency
rates by survival curve analysis were 88.4  4.2% at 12
months and 74.2  10.9% at 24 months (Fig 3).
Of the 9 limbs which suffered occlusion, 4 underwent
successful endovascular salvage, 2 were observed following
complete wound healing in the affected limb, and 3 went
on to surgical bypass. Among the patients who underwent
surgical bypass, there were 2 femoral-to-below-knee popli-
teal artery bypasses performed for early occlusions (at 1 and
3 months), and 1 femoral-anterior tibial bypass with pros-
Fig 2. Survival curve analysis demonstrating primary patency fol-
lowing endovascular intervention.
Fig 3. Survival curve analysis demonstrating assisted-primary pa-
tency following endovascular intervention.thetic conduit was performed after 3 endovascular reinter-
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was not altered by their failed endovascular interventions.
Secondary patency rates by survival curve analysis were 92.6
3.8% at 12 months and 88.9  5.1% at 24 months (Fig 4).
There was no significant difference in primary, assisted-
primary, or secondary patency between patients who un-
derwent their initial intervention for CLI (P .84, P .73,
and P  .42, respectively).
Risk factors for restenosis/occlusion. Significant
predictors or restenosis/occlusion included the presence of
cerebrovascular disease (odds ratio [OR], 6.25; 95% confi-
dence interval [CI], 1.31-29.90; P .02), hypercholester-
olemia (OR 4.85, 95% CI 1.35-17.38; P  .015), the
presence of a popliteal stent (OR, 4.28; 95% CI, 1.24-
14.73; P  .02), and patients who were current or former
smokers (OR, 4.50; 95% CI, 1.41-14.40; P  .01) (Table
II). Less than two infrapopliteal runoff vessels trended
toward being a predictor of restenosis/occlusion (OR,
2.52; 95% CI, 0.84-7.58; P  .098).
DISCUSSION
Conventional treatment of advanced PAD in patients
presenting with lifestyle-limiting claudication and CLI has
been risk factor medication and surgical intervention, re-
spectively. However, with advances in endovascular tech-
niques and equipment, the treatment paradigm for patients
with PAD has shifted. In particular, patients with anatom-
ically favorable lesions have demonstrated excellent out-
comes with endovascular therapy and are often managed
with an aggressive endovascular posture.3-7 However, this
enthusiasm for endovascular therapy has been tempered by
significant rates of restenosis and occlusion particularly for
more advanced lesions. Concomitantly, patients with such
complex lesions typically have multiple comorbidities in-
cluding advanced coronary artery disease and cerebrovas-
cular disease, making them high risk for surgical interven-
tion. Currently, the optimal treatment for patients with
Fig 4. Survival curve analysis demonstrating secondary patency
following endovascular intervention.TASC D femoropopliteal lesions remains ill-defined.The treatment of TASC D lesions relies on particular
techniques as well as equipment to optimize technical
success. In particular, these lesions, by definition are often
quite long, which may require the use of stiff wires to
optimize the ability to push across these lesions. Further-
more, as demonstrated in this series, four limbs required an
antegrade approach to improve pushability and assist in
crossing longer lesions. In addition to crossing ability,
TASC D lesions are more complex in that re-entry may be
difficult secondary to calcification or due to a suboptimal
anatomic location. Nine limbs in this series required the use
of re-entry devices thus increasing technical difficulty. Our
overall technical success, selectively utilizing the aforemen-
tioned techniques was 89%. This is less than our previous
reported 98% technical success for TASC B and C lesions.
However, this is not dissimilar from other studies which
have looked at combined outcomes of endovascular treat-
ment of TASCC andD lesions. Setacci et al10 reviewed 145
patients with TASC II C and D lesions who were treated
with subintimal angioplasty and selective use of a re-entry
device and reported a technical success rate of 83.5% with a
16.5% usage rate of a re-entry device. Rabellino et al11
reviewed 234 limbs, 52% of which were TASC II D lesions
and reported initial technical success of 97%. In addition to
the technical limitations, there is also a degree of surgeons’
judgment contributing to lower technical success rates. In
cases where immediate technical success may be possible
and the long-term outcome may be predicted to be less
than ideal, procedure abandonment is more frequent, and
open surgical bypass or, in rare cases, primary amputation,
may be elected.
Limb salvage in our series was excellent, with no major
Table II. Univariate and multivariate analysis of factors
associated with restenosis/occlusion
Risk factor
Hazard
ratio
95%
confidence
interval
P
value
Univariate analysis
Claudication 1.85 0.70-4.86 .21
Critical limb ischemia 0.80 0.30-2.13 .66
Cerebrovascular disease 2.20 0.61-7.97 .23
Chronic renal insufficiency 0.60 0.17-2.12 .43
Congestive heart failure 0.79 0.22-2.88 .72
Current smoker 1.56 0.50-4.86 .44
Diabetes mellitus 1.81 0.71-4.59 .22
Former smoker 1.70 0.68-4.26 .26
Hypercholesterolemia 2.27 0.82-6.28 .12
Hypertension 1.13 0.34-3.74 .85
Male sex 1.56 0.62-3.92 .34
Popliteal stent 1.74 0.70-4.36 .24
2 infrapopliteal runoff vessels 1.56 0.62-3.92 .34
Multivariate analysis
Cerebrovascular disease 6.25 1.31-29.80 .02
Current or former smoker 4.50 1.41-14.40 .01
Hypercholesterolemia 4.85 1.35-17.38 .02
Popliteal stent 4.28 1.24-14.73 .02
2 infrapopliteal runoff vessels 2.53 0.84-7.58 .10amputations during the follow-up time. There was a 15%
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of arterial disease treated. Furthermore, 89% of patients
who presented with tissue loss went on to significant or
complete wound healing during follow-up. It should be
noted that this study was not reviewed in an intention-to-
treat manner, and select patients who initially failed endo-
vascular interventions did go on to have primary major
amputations. Regardless, following successful endovascular
recanalization, adequate limb salvage rates can be achieved.
As with traditional surgical bypass, this is in large part due
to the immediate hemodynamic improvement following
successful recanalization, as demonstrated by themean ABI
increase of 0.49.
During a follow-up period with a mean of approxi-
mately 11 months, nearly one-fourth of the population
expired. This highlights the fact that patients with advanced
PAD are at very high risk of death from cardiovascular
events, not only perioperatively but also in the months to
years following their diagnosis of PAD as well. Data from
the Reduction of Atherothrombosis for Continued Health
(REACH) dataset established that patients with known
PAD had a 21.1% incidence of cardiovascular death, myo-
cardial infarction, stroke, or hospitalization for an athero-
thrombotic event compared to 15.2% for patients with a
diagnosis of coronary artery disease alone or 14.5% for
patients with a diagnosis of cerebrovascular disease alone in
the first year following their initial diagnosis.12 Further-
more, these event rates increased with the number of
symptomatic arterial disease locations, starting at 12.6% for
patients with one involved arterial bed to 26.3% for patients
with three symptomatic arterial disease locations. In addi-
tion to the immediate postoperative risk in patients with
advanced PAD, consideration must be given to the long-
term risk and outcomes in such patients. Particularly, the
impact of a major operation such as an infrainguinal bypass
with special consideration given to the time required for
recovery in this elderly cohort must be considered. Unlike
bypass, endovascular intervention may be performed with
minimal physiologic impact on this often critically ill pa-
tient population. In our current series, there was only one
systemic complication directly related to the procedure
with an overall periprocedural complication rate of 6.3%.
Conversely, in a recent review of data obtained through the
National Surgical Quality Improvement Program (NSQIP)
on patients undergoing infrainguinal bypass, major compli-
cations occurred in 18.7% patients, including a 9.4% rate of
wound infections.13 Furthermore, major systemic compli-
cations occurred in 5.9% of patients. Clearly, an endovas-
cular approach obviates the need for incisions, which often
create new wound issues in these compromised extremities.
Restenosis and occlusion continue to complicate endo-
vascular interventions in nearly all arterial beds. Previous
studies have demonstrated worse outcomes with more ad-
vanced TASC classification, and TASC D classification,
alone has been shown to be a predictor of resteno-
sis.5,6,14,15 Although not directly comparable given the
retrospective nature of the two studies, our previously
reported data on TASC B and C femoropopliteal lesionsdemonstrated assisted-primary patency rates of 89.3% at 12
months and 87.1% at 24 months and secondary patency
rates of 94.0% at 12 months and 94.0% at 24 months.
Comparatively, for the TASC D limbs in this series, the
assisted-primary and secondary patency rates were 88.4% at
12 months and 74.2% at 24 months and 92.6% at 12
months and 88.9% at 24 months, respectively. Given the
long length of these lesions or their popliteal location, such
patency rates are not unexpected. However, it should be
noted that the majority of these restenoses can be treated
using endovascular techniques. Furthermore, a large num-
ber of the limbs that go on to occlusion can be salvaged
through an endovascular approach. Close surveillance us-
ing frequent noninvasive testing including both arterial
duplex and ABI measurement in combination with a clini-
cal assessment appear to be helpful in maintaining patency
of these lesions.
Predictors of restenosis/occlusion in this study were
cerebrovascular disease, hypercholesterolemia, the pres-
ence of a popliteal stent, and patients who were current or
former smokers. The exact cause-effect relationship of ce-
rebrovascular disease on restenosis is unclear and can only
be postulated to be a predictor of more advanced systemic
atherosclerotic disease. Similarly, hypercholesterolemia
may be another marker of more aggressive disease. We have
previously demonstrated hypercholesterolemia to be a pre-
dictor of restenosis in TASC B and C lesions, but the exact
mechanism remains ill-defined.6 Given the significant con-
tribution of tobacco use to atherosclerotic disease, it is not
surprising that smokers were at a higher risk for restenosis
and occlusion as has been previously demonstrated.16 The
presence of a stent in the popliteal segment places a rigid
stent at an area of repetitive motion and stress, leading to an
increased rate of restenosis, with or without the presence of
a stent fracture. Although prospective, randomized data
regarding this are lacking, from our experience and that of
others, avoidance of extending stents into the distal SFA
and proximal popliteal appears to be beneficial in reducing
restenosis. Initial undersizing of balloons, long inflation
times, and not routinely placing stents in nonflow-limiting
dissections appear to be the best means of avoiding popli-
teal artery stent placement.
This study has a number of limitations, the most im-
portant of which is its retrospective nature. Patient selec-
tion and treatment modality were not standardized. Addi-
tionally, this was not designed as an intention-to-treat
study and the primary goal of this review was to determine
the outcomes and durability of successful endovascular
interventions on TASC II D lesions. As such, patients who
did not undergo successful primary interventions were ex-
cluded from the analysis. Furthermore, although data have
been derived based on survival curve analysis, the follow-up
time is limited, and longer-term follow-up will be necessary
to determine the durability of these interventions.
CONCLUSION
Endovascular interventions for TASC II D lesions can
be safely performed with excellent hemodynamic improve-
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population. Restenosis is not uncommon in these complex,
typically lengthy lesions that mandate strict follow-up uti-
lizing noninvasive arterial studies. Cerebrovascular disease,
hypercholesterolemia, the presence of a popliteal stent, and
tobacco use all appear to be associated with higher rates of
recurrence. Further follow-up is necessary to determine the
long-term efficacy of these interventions. Additionally, fu-
ture studies regarding the cost-effectiveness of aggressive
endovascular approaches compared to conventional surgi-
cal bypass will need to be undertaken to help define the role
of these techniques in the treatment of advanced peripheral
vascular disease.
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